Aquestive Therapeutics, Inc. AQST Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $50.27M-7.3% | $44.55M-22.6% | $43.4M-26.3% | $44.13M-24.4% | $54.23M+5.3% | ||
| $18.37M+7.2% | $18.56M+3.8% | $17.24M-4.4% | $17.17M-6.6% | $17.14M-16.3% | ||
| $31.9M-14.0% | $25.99M-34.5% | $26.16M-36.0% | $26.96M-32.5% | $37.09M+19.6% | ||
| 63.5%-4.9pp | 58.3%-10.6pp | 60.3%-9.1pp | 61.1%-7.4pp | 68.4%+8.2pp | ||
| $16.04M-18.6% | $17.19M-15.2% | $18.91M+3.6% | $19.65M+21.5% | $19.71M+27.2% | ||
| $71.75M+22.5% | $79.85M+59.1% | $63.04M+44.2% | $59.91M+53.7% | $58.56M+67.4% | ||
| $106.16M+11.3% | $115.6M+30.9% | $99.19M+24.0% | $96.73M+31.5% | $95.41M+34.5% | ||
| -$55.89M-35.7% | -$71.05M-131% | -$55.79M-164% | -$52.6M-246% | -$41.18M-112% | ||
| -111.2%-35.2pp | -159.5%-106pp | -128.6%-92.7pp | -119.2%-93.2pp | -75.9%-38.2pp | ||
| $11.24M+1.1% | $11.12M0.0% | $11.12M+4.8% | $11.12M+22.3% | $11.12M+44.7% | ||
| -$68.91M-27.0% | -$83.78M-89.8% | -$68.99M-96.6% | -$65.06M-153% | -$54.25M-90.2% | ||
| -$68.91M-27.1% | -$83.78M-89.8% | -$68.98M-96.0% | -$65.04M-153% | -$54.24M-88.6% | ||
| -137.1%-37.1pp | -188.1%-111pp | -158.9%-99.2pp | -147.4%-103pp | -100%-44.2pp | ||
| -$0.62-5.1% | -$0.79-51.9% | -$0.71-54.3% | -$0.70-94.4% | -$0.59-37.2% | ||
| -$55.37M-36.6% | -$70.5M-135% | -$55.23M-175% | -$52.02M-270% | -$40.53M-122% | ||
| -110.1%-35.4pp | -158.3%-106pp | -127.3%-93.2pp | -117.9%-93.8pp | -74.7%-39.3pp | ||
| -$55.89M-35.7% | -$71.05M-131% | -$55.79M-164% | -$52.6M-246% | -$41.18M-112% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Aquestive Therapeutics, Inc.'s revenue?
- Aquestive Therapeutics, Inc. (AQST) generated $50.3M in revenue over the trailing twelve months, down 7.3% year over year.
- Is Aquestive Therapeutics, Inc. profitable?
- Aquestive Therapeutics, Inc. is not currently profitable: it reported a net loss of $68.9M over the trailing twelve months, a -137.1% net margin.
- What are Aquestive Therapeutics, Inc.'s profit margins?
- Gross margin is 63.5% and operating margin is -111.2%, with a -137.1% net margin.
- What is Aquestive Therapeutics, Inc.'s earnings per share?
- Aquestive Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-0.62.
- Where does Aquestive Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
